Guanfacine extended release for the treatment of attention-deficit/ hyperactivity disorder in children and adolescents

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 11, 2014, Pages 1601-1610

  Connor, Daniel F ^a   Arnsten, Amy Ft ^b   Pearson, Geraldine S ^a   Greco, Gabriella F ^c  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Attention deficit hyperactivity disorder; Child; Guanfacine extended release; 2A adrenoreceptor agonist

Indexed keywords

GUANFACINE; PSYCHOSTIMULANT AGENT; CENTRAL STIMULANT AGENT; DELAYED RELEASE FORMULATION;

ABDOMINAL PAIN; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; DIZZINESS; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG LABELING; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; LETHARGY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; POSTMARKETING SURVEILLANCE; PREFRONTAL CORTEX; SEDATION; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; ANIMAL; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DELAYED RELEASE FORMULATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADOLESCENT; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; GUANFACINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84904162742     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.930437     Document Type: Article

References (59)

1. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46(7):894-921
2. Centers for Disease Control and Prevention, United States. Increasing prevalence of parent-reported attentiondeficit/hyperactivity disorder among children-United States, 2003 and 2007. MMWR Morb Mortal Wkly Rep 2010;59:1439-43
3. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163(4):716-23
4. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164(6):942-8
5. Barkley RA, Fischer M, Smallish L, et al. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 2006;45(2):192-202
6. Klein RG, Mannuzza S, Olazagasti MA, et al. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Arch Gen Psychiatry 2012;69(12):1295-303
7. Barkley RA, Fischer M, Smallish L, et al. Young adult follow-up of hyperactive children: antisocial activities and drug use. J Child Psychol Psychiatry 2004;45(2):195-211
8. Barkley RA, Fischer M. The unique contribution of emotional impulsiveness to impairment in major life activities in hyperactive children as adults. J Am Acad Child Adolesc Psychiatry 2010;49(5):503-13
9. Doshi JA, Hodgkins P, Kahle J, et al. Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry 2012;51(10):990-1002.e2
10. Le HH, Hodgkins P, Postma MJ, et al. Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case. Eur Child Adolesc Psychiatry 2013. [Epub ahead of print]
11. Feldman HM, Reiff MI. Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents. N Engl J Med 2014;370(9):838-46
12. Kelly C, Biswal BB, Craddock RC, et al. Characterizing variation in the functional connectome: promise and pitfalls. Trends Cog Sci 2012;16(3):181-8
13. Castellanos FX, Proal E. Large-scale brain systems in ADHD: beyond the prefrontal-striatal model. Trends Cog Sci 2012;16(1):17-26
14. Shaw P, Eckstrand K, Sharp W, et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc Natl Acad Sci USA 2007;104(49):19649-54
15. Shaw P, Lalonde F, Lepage C, et al. Development of cortical asymmetry in typically developing children and its disruption in attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry 2009;66(8):888-96
16. Barkley RA. Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. 3rd edition. Guilford; NY, USA: 2006
17. Faraone SV, Mick E. Molecular genetics of attention deficit hyperactivity disorder. Psychiatr Clin North Am 2010;33(1):159-80
18. Devilbiss DM, Berridge CW. Cognition-enhancing doses of methylphenidate preferentially increase prefrontal cortex neuronal responsiveness. Biol Psychiatry 2008;64(7):626-35
19. Gamo NJ, Wang M, Arnsten AF. Methylphenidate and atomoxetine enhance prefrontal function through alpha2-adrenergic and dopamine D1 receptors. J Am Acad Child Adolesc Psychiatry 2010;49(10):1011-23
20. Spencer RC, Klein RM, Berridge CW. Psychostimulants act within the prefrontal cortex to improve cognitive function. Biol Psychiatry 2012;72(3):221-7
21. Bukstein OG, Head J. Guanfacine ER for the treatment of adolescent attentiondeficit/hyperactivity disorder. Expert Opin Pharmacother 2012;13(15):2207-13
22. Connor DF. Stimulants. In: Barkley RA, editor. Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. Guildford; NY, USA: 2006. p. 608-47
23. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41(2 Suppl):26S-49S
24. Sorkin EM, Heel RC. Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 1986;31(4):301-36
25. Arnsten AF, Steere JC, Hunt RD. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1996;53(5):448-55
26. Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34(1):50-4
27. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001;158(7):1067-74
28. Cruz MP. Guanfacine extended-release tablets (intuniv), a nonstimulant selective alpha(2A)-adrenergic receptor agonist for attention-deficit/ hyperactivity disorder. P T 2010;35(8):448-51
29. Engberg G, Eriksson E. Effects of alpha 2-adrenoceptor agonists on locus coeruleus firing rate and brain noradrenaline turnover in Nethoxycarbonyl-2- ethoxy-1,2-dihydroquinoline (EEDQ)-treated rats. Naunyn Schmiedebergs Arch Pharmacol 1991;343(5):472-7
30. U'Prichard DC, Bechtel WD, Rouot BM, et al. Multiple apparent alpha-noradrenergic receptor binding sites in rat brain: effect of 6-hydroxydopamine. Mol Pharmacol 1979;16(1):47-60
31. Wang M, Ramos BP, Paspalas CD, et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 2007;129(2):397-410.
32. Arnsten AF, Jin LE. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. Yale J Biol Med 2012;85(1):45-58
33. Kim S, Bobeica I, Gamo NJ, et al. Effects of alpha-2A adrenergic receptor agonist on time and risk preference in primates. Psychopharmacol (Berl) 2012;219(2):363-75
34. Arnsten AF. The use of alpha2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder. Expert Rev Neurother 2010;10:1595-605
35. Arnsten AFT. Stress signaling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci 2009;32:267-87
36. Boellner SW, Pennick M, Fiske K, et al. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy 2007;27(9):1253-62
37. Sallee F, Connor DF, Newcorn JH. A review of the rationale and clinical utilization of alpha2-adrenoceptor agonists for the treatment of attentiondeficit/hyperactivity and related disorders. J Child Adolesc Psychopharmacol 2013;23(5):308-19
38. Swearingen D, Pennick M, Shojaei A, et al. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. Clin Ther 2007;29(4):617-25
39. Roesch B, Corcoran ME, Fetterolf J, et al. Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate. Drugs R D 2013;13(2):119-28
40. Roesch B, Corcoran M, Haffey M, et al. Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release. Drugs R D 2013;13(1):53-61
41. Wilson MF, Haring O, Lewin A, et al. Comparison of guanfacine versus clonidine for efficacy, safety and occurrence of withdrawal syndrome in step-2 treatment of mild to moderate essential hypertension. Am J Cardiol 1986;57(9):43E-9E
42. Kisicki JC, Fiske K, Lyne A. Phase I, double-blind, randomized, placebocontrolled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years. Clin Ther 2007;29(9):1967-79
43. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebocontrolled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008;121(1):e73-84.
44. Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebocontrolled trial. J Am Acad Child Adolesc Psychiatry 2009;48(2):155-65.
45. DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD rating scale-IV: checklists, norms, and clinical interpretation. Guilford Press; NY, USA: 1998
46. Spencer TJ, Greenbaum M, Ginsberg LD, et al. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19(5):501-10
47. Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2012;51(1):74-85.e2
48. Biederman J, Melmed RD, Patel A, et al. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr 2008;13(12):1047-55
49. Sallee FR, Lyne A, Wigal T, et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2008;19(3):215-26
50. Newcorn JH, Stein MA, Childress AC, et al. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. J Am Acad Child Adolesc Psychiatry 2013;52(9):921-30
51. Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attentiondeficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs 2010;24(9):755-68.
52. Connor DF, Rubin J. Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents. Drugs Today (Barc) 2010;46(5):299-314
53. Kollins SH, Lopez FA, Vince BD, et al. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2011;21(2):111-20
54. Department of Health and Human Services FaDA, Office of Surveillance and Epidemiology. Pediatric postmardet adverse event review, guanfacine hydrochloride, extended-release. 2013. Available from: www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/ UCM367048.pdf2013
55. ClinicalTrials.gov. database U.S. National Institutes of Health, Washington DC; 2014. Available from: http://clinicatrials.gov/ct2/results?term= guanfacine+ext3nded +release+AND+ADHD&Search=Search
56. Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry 2014;53(2):153-73
57. Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry 2014;53(2):174-87
58. Connor DF, Grasso DJ, Slivinsky MD, et al. An open-label study of guanfacine extended release for traumatic stress symptoms in children and adolescents. J Child Adolesc Psychopharmacol 2013;23(4):244-51
59. Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006;63(6):679-85